Welcome to our dedicated page for Sanofi FR news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi FR stock.
Sanofi reports news as a global biopharmaceutical issuer with American depositary shares traded under SNY. Company updates center on medicines and vaccines built around immunology, specialty care, rare diseases, diabetes, respiratory disease and infectious-disease prevention, including recurring developments for products such as Dupixent, BEYFORTUS, insulins and pipeline candidates.
Sanofi news also covers clinical and regulatory milestones, collaborations with biotechnology and diagnostics partners, patient-access programs, community health initiatives, leadership changes and capital-allocation actions. As a foreign issuer, updates may reflect both parent-company announcements and ADR-related public-company disclosures.
Seagen and Sanofi have entered an exclusive collaboration to develop and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. This partnership combines Sanofi's monoclonal antibody technology with Seagen's ADC technology. Both companies will co-fund global development activities and share future profits. Sanofi will also provide undisclosed payments for the selected targets. The first target has already been designated, aligning with Seagen's strategy to advance cancer treatment options.
Regeneron and Sanofi announced positive Phase 3 trial results for Dupixent (dupilumab) 300 mg weekly in treating eosinophilic esophagitis (EoE), a chronic inflammatory disease. The trial showed a 64% reduction in disease symptoms after 24 weeks compared to placebo, with 59% of Dupixent patients achieving histological remission. The safety profile was consistent with previous studies. Regulatory filings are expected in 2022. EoE affects around 160,000 patients in the U.S., highlighting the potential market for Dupixent in this indication.
Summary not available.
Sanofi announced a collaboration with Breast International Group (BIG), EORTC, and AFT to initiate the Phase 3 AMEERA-6 study, focusing on the oral selective estrogen receptor degrader (SERD) amcenestrant for estrogen receptor-positive breast cancer in patients unable to continue aromatase inhibitor therapy. The trial aims to evaluate amcenestrant's efficacy and safety against tamoxifen. Sanofi will sponsor the study, which is crucial for providing alternatives in adjuvant therapy to combat disease recurrence.
Sanofi and Merck have announced that Vaxelis, the first hexavalent combination vaccine in the U.S., is now available. This vaccine protects against six diseases: diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B, administered in three doses to children aged 6 weeks to 4 years. The vaccine aims to reduce the number of shots children need, improving vaccination coverage. Vaxelis has been included in the CDC's immunization schedule and will be distributed through various channels. The collaboration reflects a commitment to enhancing pediatric health.
Sanofi has announced a three-year research collaboration with Stanford University School of Medicine, aiming to deepen the understanding of immunology and inflammation. The partnership will explore autoimmune diseases and inflammatory conditions, with funding for up to three joint programs annually. Initial projects will focus on type 2 inflammation, T cell mechanisms in autoimmunity, and immune-related adverse events. This collaboration strengthens Sanofi's commitment to research and innovation within immunoscience.
Sanofi has partnered with Moderna to manufacture up to 200 million doses of its COVID-19 vaccine, utilizing its Ridgefield, NJ facility starting September 2021. This represents Sanofi's third manufacturing commitment in response to the pandemic, having previously supported BioNTech and Johnson & Johnson. The company is also developing its COVID-19 vaccine candidates in collaboration with GSK and Translate Bio. Sanofi aims to enhance global vaccine supply while continuing its internal vaccine development efforts.
On April 7, 2021, Sanofi announced the creation of Sanofi Global Health, a new nonprofit unit aimed at enhancing access to essential medicines in 40 lower-income countries. The initiative will provide 30 medicines across various therapeutic areas, alongside support for healthcare professionals. Additionally, Sanofi plans to donate 100,000 vials of treatments annually for rare diseases. The company also committed to reducing greenhouse gas emissions by 55% by 2030 and implementing zero plastic packaging for vaccines by 2027, while promoting diversity within its workforce.
The FDA has approved Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) after one to three prior treatments. The approval is based on the Phase 3 IKEMA study, which demonstrated a 45% reduction in disease progression or death risk. Sarclisa now has two FDA-approved combinations for RRMM. Despite challenges in treating relapsed MM, the approval positions Sarclisa as a potential standard of care, enhancing its market potential.
Biond Biologics has signed an exclusive worldwide license agreement with Sanofi (SNY) for the development of BND-22, a humanized IgG4 antibody aimed at treating solid tumors. Biond will receive a $125 million upfront payment and potentially over $1 billion in milestones and royalties. BND-22 targets the inhibitory ILT2 receptor and has shown promising preclinical results by activating immune responses against tumors. The first-in-human phase 1a study is set to start by mid-2021, with Sanofi overseeing later clinical development.